M&A
EQT acquires molecular diagnostics company Qiagen in €10.8B deal
Biotech
M&A
Key Facts
Signal Type
M&A
Industry
Biotech
Companies
Qiagen, EQT, Thermo Fisher, Hologic, Agilent
Date
Private equity firm EQT is acquiring Netherlands-based Qiagen in a deal valued at €10.8 billion ($12.1 billion) enterprise value, including $1.1 billion in net debt. The transaction comes six years after Thermo Fisher's failed $12.5 billion bid for the company, which was blocked by shareholder opposition. Qiagen's board has unanimously approved the buyout, and the company's shares jumped on the announcement. This follows the appointment of Jonathan M. Pratt as CEO just two months ago, after the unexpected departure of long-time CEO Thierry Bernard in November 2025.
Qiagen (target) will continue operating under its name and brand but will shift from public to private ownership. EQT (acquirer) gains control of a leading molecular diagnostics and life sciences company. Employees, shareholders, and customers of Qiagen will face organizational and operational changes. Competitors such as Thermo Fisher, Hologic, and Agilent are also affected as the med-tech M&A landscape consolidates.
The acquisition is part of a broader wave of med-tech consolidation. Recent deals include Hologic's acquisition of Reveal Genomics, Agilent's purchase of digital pathology company Proscia, and asset transfers involving Myriad Genetics, BioReference Health, and Labcorp. Qiagen's move to private ownership gives it greater flexibility to invest for the long term, potentially accelerating R&D and market expansion. This may pressure competitors to seek their own strategic moves or partnerships.
Monitor how the integration under new CEO Jonathan Pratt unfolds, particularly any shifts in Qiagen's technology stack, IT infrastructure, or operational processes. These changes could create immediate needs for third-party services in migration, cybersecurity, and post-merger integration. Also watch for competitor responses, such as further acquisitions or strategic pivots, as Qiagen gains newfound flexibility.
Source:
Fierce BiotechGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
